NASDAQ:IFRX

InflaRx Q3 2025 Earnings Results & Report

InflaRx logo
$1.15 -0.03 (-2.54%)
Closing price 04:00 PM Eastern
Extended Trading
$1.12 -0.03 (-2.52%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

InflaRx met analyst expectations on both earnings and revenue in its Q3 2025 results, released November 10, 2025. The company reported EPS of -$0.16 versus the -$0.16 consensus estimate, while revenue of $30 thousand matched the $30 thousand estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
4:00 PM ET

InflaRx EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.16
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

InflaRx Revenue Results

Actual Revenue
$30 thousand
Expected Revenue
$30 thousand
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Earnings Documents

InflaRx Q3 2025 Earnings FAQ

InflaRx (NASDAQ:IFRX) reported earnings of -$0.16 per share for Q3 2025, matching the consensus estimate of -$0.16. The report was announced on Monday, November 10, 2025.

InflaRx reported revenue of $30 thousand for Q3 2025, against a consensus estimate of $30 thousand.

InflaRx Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
InflaRx (IFRX) AI Stock Analysis
InflaRx Stock Gets Stronger EPS Forecast from HC Wainwright
See More InflaRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InflaRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InflaRx and other key companies, straight to your email.

About InflaRx

InflaRx (NASDAQ:IFRX) is a biotechnology company that develops therapies for inflammatory and autoimmune diseases. Its research focuses on the complement system, a part of the immune system that can contribute to inflammation and tissue damage.

The company’s lead antibody, vilobelimab, targets the complement protein C5a. In 2023, the U.S. Food and Drug Administration granted emergency use authorization for vilobelimab, marketed as Gohibic, for certain hospitalized adults with COVID-19. InflaRx is also investigating the drug in other inflammatory conditions.

Founded in 2007, InflaRx is headquartered in Jena, Germany, and has operations in the United States. Co-founder Niels C. K. Riedemann has served as the company’s chief executive officer.

View InflaRx Profile